Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

NCT03978520 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03978520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03978520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
July 25, 2019
Completion date
July 14, 2022
Enrollment
341 (actual)
Sites
160

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)